Overview

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

Status:
Unknown status

Trial end date:
2020-08-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of apatinib plus EGFR-TKI as first line treatment in patients with non-squamous NSCLC harboring EGFR mutation.

Phase:

N/A

Details

Lead Sponsor:

Hebei Medical University Fourth Hospital

Treatments:

Apatinib